Onconetix, Inc. Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment
Onconetix, Inc. (ONCO) reported Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment of $146.80 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Income Statement › Other Income
us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments · last filed 2026-03-13
- Onconetix, Inc. defined benefit plan, net periodic benefit cost (credit), gain (loss) due to curtailment for the quarter ending 2025-12-31 was $0.00.
- Onconetix, Inc. defined benefit plan, net periodic benefit cost (credit), gain (loss) due to curtailment for the quarter ending 2025-09-30 was $146.80K.
- Onconetix, Inc. defined benefit plan, net periodic benefit cost (credit), gain (loss) due to curtailment for fiscal 2025 was $146.80K.
| Period end | Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment 3 month | Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment 6 month | Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment 9 month | Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $146.80K derived: sum of 2 quarters · filed 2026-03-13 | $146.80K 10-K · filed 2026-03-13 | |
| 2025-09-30 | $146.80K 10-Q · filed 2025-11-13 | $146.80K 10-Q · filed 2025-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |